Rights Issue 2026
Immunovia is currently carrying out an issue of units of up to SEK 63 million, at full subscription, to accelerate the commercialisation of PancreaSure® – a blood test for early detection of pancreatic cancer. Investors have the opportunity to participate in the issue during the subscription period 9–23 November 2026.
Immunovia accelerates sales of PancreaSure® in the US
Pancreatic cancer is most often detected too late, when surgery is no longer possible. Immunovia’s blood test PancreaSure is designed to detect the disease at stages I and II in people in the risk group, when it is still curable.
PancreaSure was launched in the US in September 2025 and is currently used at around 30 surveillance centres for high-risk patients, including ten of the country’s top twenty cancer hospitals. Immunovia has initiated the process to obtain full reimbursement from Medicare, the largest public health insurance programme in the US, which could open up significantly greater sales of PancreaSure in the US.
With full subscription in the rights issue, Immunovia will receive approximately SEK 63 million before costs. The proceeds will be used to accelerate the commercialisation of PancreaSure in the US, initiate new clinical studies that strengthen the basis for reimbursement, and strengthen the company’s working capital. With full exercise of the warrants of series TO 4, the Company may receive additional capital in May 2027.
Q&A about the rights issue with CEO Jeff Borcherding
Read the interview with CEO Jeff Borcherding on how issue proceeds will be used, the company’s milestones during 2027: from licensing agreements in Asia to a commercialisation partner in the US, and why the clinical studies are key to reimbursement.
Read here
Interview with Sarah DeDiemar on the commercialization of PancreaSure
Read the interview with Sarah DeDiemar, VP Marketing and Sales, on what draws surveillance programs to PancreaSure, the next step in commercialization: from pilot sales to routine ordering, and the expansion to gastroenterology group practices.
Read hereCEO on upcoming milestones in 125 seconds
Jeff Borcherding presents the key upcoming events in 2027 for Immunovia’s path towards increased sales of PancreaSure in the US.
Jeff Borcherding presents Immunovia
Watch a new presentation on the company's strategy and operational activities to increase the use of PancreaSure, achieve reimbursement and enable earlier cancer treatment for patients in the USA.
